These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 6439678)

  • 1. Immunization against Mycoplasma pneumoniae disease: a review.
    Barile MF
    Isr J Med Sci; 1984 Oct; 20(10):912-5. PubMed ID: 6439678
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Protective efficacy of Mycoplasma pneumoniae polysaccharides.
    Brunner H
    Isr J Med Sci; 1981 Jul; 17(7):678-81. PubMed ID: 6793538
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunogenicity and protective effect of hemolysis mutants of Mycoplasma pneumoniae.
    Yayoshi M; Araake M; Hayatsu E; Takezawa T; Yoshioka M
    Microbiol Immunol; 1985; 29(11):1029-37. PubMed ID: 3937957
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Superiority of the chimpanzee animal model to study the pathogenicity of known Mycoplasma pneumoniae and reputed mycoplasma pathogens.
    Barile MF; Grabowski MW; Snoy PJ; Chandler DK
    Isr J Med Sci; 1987 Jun; 23(6):556-60. PubMed ID: 3117729
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Immunoprophylaxis of mycoplasmosis (a review of the literature)].
    Kolesnikov LV
    Voen Med Zh; 1981 Jan; (1):40-4. PubMed ID: 6782753
    [No Abstract]   [Full Text] [Related]  

  • 6. Development of protective anti-Mycoplasma pneumoniae antibodies after immunization of guinea pigs with the combination of a P1-P30 chimeric recombinant protein and chitosan.
    Hausner M; Schamberger A; Naumann W; Jacobs E; Dumke R
    Microb Pathog; 2013 Nov; 64():23-32. PubMed ID: 23948467
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hamster challenge potency assay for evaluation of Mycoplasma pneumoniae vaccines.
    Barile MF; Chandler DK; Yoshida H; Grabowski MW; Razin S
    Infect Immun; 1988 Sep; 56(9):2450-7. PubMed ID: 3137170
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hamster challenge potency assay for evaluation of Mycoplasma pneumoniae vaccines.
    Barile MF; Chandler DK; Yoshida H; Grabowski MW; Harasawa R; Ahmed OA
    Isr J Med Sci; 1981 Jul; 17(7):682-6. PubMed ID: 6793539
    [No Abstract]   [Full Text] [Related]  

  • 9. Further studies on the Mycoplasma pneumoniae extract: ciliostatic and cell recruitment activities.
    Chandler DK; Grabowski MW; Rabson AS; Barile MF
    Isr J Med Sci; 1987 Jun; 23(6):580-4. PubMed ID: 3117732
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of monoclonal antibodies to the attachment-tip on experimental Mycoplasma pneumoniae infection of hamsters. A preliminary report.
    Brunner H; Feldner J; Bredt W
    Isr J Med Sci; 1984 Sep; 20(9):878-81. PubMed ID: 6439683
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Field trial of two dual vaccines against Mycoplasma agalactiae and Mycoplasma mycoides subsp. mycoides (large colony type) in goats.
    de la Fe C; Assunção P; Saavedra P; Tola S; Poveda C; Poveda JB
    Vaccine; 2007 Mar; 25(12):2340-5. PubMed ID: 17239497
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mycoplasma pneumoniae infections.
    Brunner H
    Isr J Med Sci; 1981 Jul; 17(7):516-23. PubMed ID: 6793535
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mycoplasma infections of the human respiratory tract.
    Jacobs E
    Wien Klin Wochenschr; 1997 Aug; 109(14-15):574-7. PubMed ID: 9286062
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analysis of the immunoproteome of Mycoplasma mycoides subsp. mycoides small colony type reveals immunogenic homologues to other known virulence traits in related Mycoplasma species.
    Jores J; Meens J; Buettner FF; Linz B; Naessens J; Gerlach GF
    Vet Immunol Immunopathol; 2009 Oct; 131(3-4):238-45. PubMed ID: 19443045
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Novel vaccines against M. tuberculosis].
    Okada M
    Kekkaku; 2006 Dec; 81(12):745-51. PubMed ID: 17240920
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mycoplasma pneumoniae reinfection and vaccination: protective oral vaccination and harmful immunoreactivity after re-infection and parenteral immunization.
    Cimolai N; Cheong AC; Morrison BJ; Taylor GP
    Vaccine; 1996 Oct; 14(15):1479-83. PubMed ID: 8994325
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Associated live vaccine against influenza, adenovirus type 4 and Mycoplasma pneumoniae].
    Smorodintsev AA; Kolesnikov LV
    Tr Inst Im Pastera; 1982; 58():3-13. PubMed ID: 6821264
    [No Abstract]   [Full Text] [Related]  

  • 18. Relationship between an 85 kDa protein and the protective effects of Mycoplasma pneumoniae.
    Yayoshi M; Sasaki T; Yoshioka M
    Microbiol Immunol; 1992; 36(5):455-64. PubMed ID: 1513262
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of improved attenuated and nucleic acid vaccines for heartwater.
    Collins NE; Pretorius A; van Kleef M; Brayton KA; Allsopp MT; Zweygarth E; Allsopp BA
    Dev Biol (Basel); 2003; 114():121-36. PubMed ID: 14677683
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bases for the early immune response after rechallenge or component vaccination in an animal model of acute Mycoplasma pneumoniae pneumonitis.
    Cimolai N; Mah DG; Taylor GP; Morrison BJ
    Vaccine; 1995 Feb; 13(3):305-9. PubMed ID: 7631518
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.